Clinical Trials Logo

Clinical Trial Summary

The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.


Clinical Trial Description

This is a prospective, single-arm, single-center Ib/II clinical trial that included an initial safety run-in phase with safety monitoring before the main enrollment (expansion phase).The aim of phase Ib is to evaluate the recommended phase 2 dose and dose-limiting toxicity (DLT), and the aim of phase II study is to evaluate, for the first time, the safety and efficacy of the treatment of Linperlisib combined with PD-1 blockade Camrelizumab and Pegaspargase in patients diagnosed with advanced or r/r ENKTL, respectively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06376721
Study type Interventional
Source Beijing Tongren Hospital
Contact Liang Wang, M.D.
Phone +861058268442
Email wangliangtrhos@126.com
Status Recruiting
Phase Phase 1/Phase 2
Start date April 14, 2024
Completion date October 31, 2027

See also
  Status Clinical Trial Phase
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT04620655 - RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL N/A
Not yet recruiting NCT06434467 - The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma Phase 3
Recruiting NCT04582487 - Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL N/A
Suspended NCT04828174 - Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies Phase 1
Not yet recruiting NCT05068401 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT03558412 - A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma Phase 4
Recruiting NCT05576532 - Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia Phase 2
Withdrawn NCT04860817 - A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL Early Phase 1
Recruiting NCT04004637 - CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia Phase 1
Recruiting NCT06136364 - CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study Phase 1